Thyroxine (T4) and reverse triiodothyronine are potent inhibitors of brown adipose T4 5'-deiodinase (BAT 5D). This effect does not require protein synthesis and is due to an acceleration of the rate of disappearance of the enzyme. Growth hormone (GH) also inhibits BAT 5'D but by a mechanism mediated through a long-lived messenger that correlates with growth rate. This explains the failure of BAT 5D to increase abruptly after thyroidectomy as does the type II 5'-deiodinase in pituitary and central nervous system or the BAT 5'D itself after hypophysectomy. Although virtually inactive when given acutely, triiodothyronine replacement partially reduces BAT 5D in hypophysectomized and thyroidectomized (Tx) animals probably as a result of improvement of systemic hypothyroidism and an increase in GH levels in the Tx rats. The fine balance between these inhibitory factors and the stimulatory effects of the sympathetic nervous system suggests an important physiologic role for the enzyme in this tissue.
Introduction
Abundant evidence suggests that triiodothyronine (T3)' largely accounts for the thyromimetic action of the thyroidal secretion at the cellular level. Cellular T3 may come from the plasma pool or can be made in situ by 5'-deiodination ofthyroxine (T4). The relative importance of these two sources varies from one tissue to another (1) . On one end of the spectrum are kidney, heart and skeletal muscles in which >90% ofthe T3 comes from plasma and, at the other, is the cerebral cortex where 80% of the T3 is made in situ. Because -50% of the circulating T3 in the rat (2, 3) and 75% in humans (4) is produced from extrathyroidal 5'-deiodination of T4, the latter reaction is essential for the maintenance ofthe concentration ofT3 in the tissues, regardless of the source.
The S'-deiodination of T4 is a reaction catalyzed by, at least, two types of enzymes. The type I deiodinase (5D-I) is most abundant in liver and kidney (5) (6) (7) (8) . This enzyme exhibits "ping- 1 . Abbreviations used in this paper: BAT, brown adipose tissue; bGH, bovine growth hormone; BW, body weight; 5'-D-I, type I 5'-deiodinase; S'-D-II, type II 5'-deiodinase; DTT, dithiothreitol; GH, growth hormone; a-GPD, a-glycerophosphate dehydrogenase; IGF, insulinlike growth factor; MMI, methimazole; NE, norepinephrine; PTU, propylthiouracil; rT3, reverse triiodothyronine; T3, triiodothyronine; T4, thyroxine.
pong" type kinetics, is highly sensitive to uncompetitive inhibition by propylthiouracil (PTU) (5, 7, 8) , is decreased in hypothyroidism, and is increased in hyperthyroidism (9) . This enzyme accounts for -60-70% of the extrathyroidally produced T3 in euthyroid rats (10) (11) (12) (13) (14) (15) . The type II 5'-deiodinase (5'D-II) exhibits "sequential" type kinetics, has markedly lower apparent Km for T4 and reverse T3 (rT3) than does 5'D-I and, in addition, at variance with 5D-I, T4 is the preferred substrate for this enzyme (13, 14) . 5'D-II is present in central nervous system, anterior pituitary gland, in brown adipose tissue (BAT) (16) , and in rat and human placenta ( 17) . Other essential characteristics of this enzyme are its marked increase in hypothyroid animals, the lack of significant inhibition by PTU in vivo, and its acute inhibition by T4, rT3 and, to a lesser extent, by T3 itself ( 18) . In the cerebral cortex and in the anterior pituitary of normal rats, this enzyme accounts for all the T3 generated in situ (15) .
Although during the neonatal period the CNS 5`D-Il might contribute to the serum T3 pool (19) , both the anterior pituitary and the CNS deiodinases are generally a local source of T3. In contrast, BAT 5'D-II not only is a major source of T3 for this tissue, but it can contribute significantly to the plasma pool of T3 when highly activated, and/or when the BAT mass is appropriately large. For example, in hypothyroid rats, extrathyroidal T3 production is insensitive to PTU but very sensitive to inhibition by either T4 or rT3 (20, 21) , suggesting that T3 is being generated via a type II 5'-deiodinase. During the neonatal period, when BAT is a larger fraction of the total body weight, 80% of the extrathyroidally produced T3 in euthyroid rats originates via a type II 5'-deiodinase (20) . More recently, we have found that BAT 5D-II can be stimulated markedly by the sympathetic nervous system (22) , which is reflected in greater contributions of S'D-II to the plasma pool of T3 and, further, by parallel changes in the locally-produced BAT T3 (23) . The blockade of sympathetic stimulation by the a1-antiadrenergic agent prazosin blunts the sympathetic-induced increase in enzyme activity and, also, the increments in serum and BAT T3. The parallelism between enzyme activity, plasma T3, and locally produced T3 in BAT suggests that this tissue may be an important source ofthe plasma T3 generated via 5D-II pathways. As much as 40-50% of the peripheral T3 production in adult euthyroid rats (15, 21) and 80% in neonatal rats (19) , could be generated through this pathway.
Thyroid hormone increases oxygen consumption and calorigenesis, as does stimulated BAT, but the relationships between thyroid hormone and BAT activity are largely unknown. A current hypothesis is that thyroid hormone has primarily a permissive role for the sympathetic activation of BAT (24) . The existence of BAT 5D-II, which increases both extrathyroidal and intracellular T3, suggests that the relationship may be more complex. As is the case in CNS and pituitary, BAT 5D-Il is markedly increased in hypothyroid rats (16) . In addition, and at variance with observations in the CNS and pituitary, BAT 5D-II is stimulated by the sympathetic nervous system. The studies to be described, as well as others in progress, suggest that 5D-II in BAT is under complex endocrinologic and metabolic regulation. The present report describes the effects of thyroid hormone on BAT 5D-II, and details the interactions between thyroid hormone and the sympathetic nervous system. The results also demonstrate the growth hormone (GH) is an important regulator of the enzyme in this tissue.
Methods
Animals. Male Sprague-Dawley rats (Charles River Breeding Laboratories, Inc., Wilmington, MA or Zivic-Miller Laboratories, Allison Park, PA) were used throughout. Except for some studies in chronic thyroidectomized rats and others, indicated when appropriate, most were performed in rats weighing 100-150 g. Hypothyroidism was induced by surgical thyroidectomy (Zivic-Miller) or by the administration of 0.02% methimazole (MMI) in the drinking water. Thyroidectomy was followed by parathyroid reimplant (Zivic-Miller). Hypophysectomized rats were obtained from Charles River Breeding Laboratories within 24 h ofsurgery.
Rats were maintained in a temperature-regulated room (22-250C) with cycles of light and darkness of 14 and 10 h, respectively. Hypophysectomized rats were given 5% glucose in the drinking water and, when indicated, corticosterone, 0.5 mg/100 g body weight (BW) intraperitoneally or subcutaneously. Studies in progress show that glucose is a permissive factor for elevation of BAT 5D-II after a variety of stimuli, but 5% glucose in the drinking water does not have a stimulatory effect on BAT 5D-II in intact or acutely thyroidectomized rats. Corticosterone has no effect on BAT 5D-H activity and it was used to protect the animals from the stress of the experiments.
The various experimental protocols as well as doses and route of injection are described in Results.
Hormones. T4 and T3 were obtained from Sigma Chemical Co., (St. Louis, MO) and were dissolved in 10% rat serum in 0.9% NaCI and injected subcutaneously or intravenously, as indicated. rT3 was purchased from Henning (West Berlin, Federal Republic ofGermany). Bovine GH (NIH-GH-B18) and rat GH were kindly provided by the National Pituitary Agency. Bovine GH (bGH) was injected intraperitoneally or subcutaneously as indicated dissolved in 0.01 NaHCO3, as suggested by the National Pituitary Agency. The biological activity was 3.2 U/mg; it contained 1-4% prolactin activity but negligible luteinizing hormone, folliclestimulating hormone, thyroid-stimulating hormone (TSH), and adrenocorticotropin (ACTH). Either corticosterone or corticosterone-acetate were obtained from Sigma Chemical Co., dissolved in 5-10% ethanol in 5% dextrose and injected intraperitoneally or subcutaneously, as indicated. [ '25I]T4, [121I]T3, and ["lI]rT3 were labeled as described previously (25, 26) and used either for in vivo experiments or radioimmunoassays. Norepinephrine (NE) (Sterling Drugs Inc., New York), was obtained from the local pharmacy, diluted to 400 Mg/ml in 5% glucose, and injected subcutaneously. Other drugs used were prazosin, the kind gift of Pfizer Laboratories (E. Weiss, Pharmaceutical Div.) and cycloheximide (Calbiochem-Behring Corp., San Diego, CA). Both drugs were dissolved and injected as described previously (22, 27) .
Analytical methods. 5D-II was measured as described previously (15, 16) to BAT T4 was 0.16±0.02 nM at 2 h after T4 injection. This increment has no effect on the 5'-deiodination assay. In cerebral cortex and pituitary assays, the tissue contributions were <0.10 nM. As previously reported, the amount of rT3 carried over into the assay is also negligible (29) .
a-Glycerophosphate dehydrogenase (a-GPD) was measured as described earlier (30) (31) (32) (33) and serum T4 and T3 by radioimmunoassay (33) .
The rat GH radioimmunoassay used NIADDK-rat GH-I-5 for iodination and GH-RP-2 as reference. The latter gives serum concentrations that are 40% that obtained with RP-1 (expressed as nanograms per milliliter). Fig. 1 shows that both the BAT and the cerebral cortical 5D-II activities respond in the same fashion to the acute injection of T4, with 50% suppression of the basal activity at a dose of -0.2 gg/100 g BW for both tissues. BAT 5D-I1 was also very sensitive to rT3 injection with the half-maximal suppressive dose -4.5 ,ug/I00 g BW, but was barely affected by the injection of 40 Mg/ 100 g BW T3 (Fig. 2) . Similar responses of cerebral cortex 5D-II to these iodothyronines have been reported previously (18) . Because of the markedly lower sensitivity of the enzyme to T3, a complete dose response curve to this hormone was not performed.
Effect ofT4 and T3 on the cold-stimulated BAT5'D-II. Groups of four to five normal rats were exposed to 4°C for 21 h, which stimulates the enzyme maximally. At the end of the cold exposure, the animals were injected with 1 Mg T4/100 g BW (or its vehicle), intravenously. Another group of rats received prazosin to prevent further stimulation of the enzyme by persistent norepinephrine release. The dosage was 0.4 mg/100 g BW intraperitoneally followed by 0.2 mg/100 g BW 2 h later (22) . The remaining animals received the corresponding vehicle with 2. These results confirm the findings by Goswami and Rosenberg (28) that at lower DTT concentrations it is possible to demonstrate PTU inhibition of the BAT deiodinase. However, the concentrations of PTU necessary to decrease the V.a by 50% are still 300-1,000-fold higher than those reported to reduce the V,,. of 5D-I a comparable degree. identical timing. BAT 5D-II activity was measured at the time of terminating the cold exposure or 4 h later. The results are shown in Fig. 3 . The marked elevation of 5D-II persisted over the 4 h after the cold stress and was not affected by prazosin, indicating no further adrenergic stimulation. In contrast, the intravenous injection of 1 Iug T4/100 g BW induced a marked reduction of the enzyme with return to near basal levels.
To characterize further the effect of T4 on cold-induced activation of BAT 5D-II, groups of normal animals were given single injections of 1 ,ug T4/100 g BW at various times before 4 h cold stress and killed at the end of the cold exposure (Fig.  4) . The 4 h of cold stress induced a marked increment in the enzyme activity in the control rats, as shown by the hatched area. The injection ofT4 had a suppressive effect on the response when given at -4 h and just prior to cold exposure. There was no effect of T4 given 16 h prior to cold stress. These results were mirrored by the serum T4 concentrations. This was normal in the animals injected at -20 h, whereas in those injected at -8 or -4 h, it was -70 and 100% greater than in the uninjected controls. These results indicate that the effect of T4 is not mediated by a long-lived messenger, but could be related to an effect of T4 requiring its presence in the tissue. As indicated in Methods, these results cannot be attributed to dilution of the substrate in the assay by T4 contained in the tissue preparation.
In agreement with the poor suppression by T3 ofthe elevated BAT 51)-II in hypothyroid animals, this hormone did not affect the response to 4 h of cold exposure in euthyroid animals (Fig. 5) . Furthermore, T3-induced hyperthyroidism augmented the response to sympathetic stimulation, e.g., to the injection of norepinephrine (Table I ). This effect of T3 resulted in part from the fall in serum T4 subsequent to the T3-induced suppression ofTSH, since the injection ofsufficient T4 to maintain its serum concentration, together with the T3, prevented the increased response. However, another part of the effect was related to the hyperthyroidism, in that the response to NE in rats injected with 0.6 ,ug ofT3/10 g BW was only 25% ofthat seen in rats injected with 50 ug of T3/l00 g BW 18 h prior to the NE challenge. In We also explored the effect of cycloheximide on the T4-induced suppression of BAT 51D-II. Because earlier studies had shown that thyroid hormone accelerated the fractional turnover rate of the 5D-IH in cortex and pituitary (27) , we measured activity at various times after injecting cycloheximide. Groups of four to five animals were exposed to 40C overnight and were then given 10 mg/I00 g BW of cycloheximide (intraperitoneally) and either 1 gg ofT4/100 g BW or its vehicle intravenously. The half time of disappearance of the enzyme activity in the control animals was -100 min ( Fig. 6) , whereas in those injected with T4, the enzyme levels decreased with a half time of -35 min (P < 0.001). In pilot experiments, 5 mg of cycloheximide/100 g BW had reduced [3H]leucine incorporation into TCA precipitable material by 68% in rats stimulated with NE. These results suggest that the suppressive effect of T4 on BAT 5D-I does not require protein synthesis.
Response ofBAT5'D-II to thyroidectomy or hypophysectomy. Because BAT 5'D-II is markedly elevated in chronically hypothyroid rats, we examined BAT 5D-II at various intervals after thyroidectomy. Much to our surprise, and in contrast to what occurs in cerebral cortex and pituitary gland, the BAT enzyme remained low for at least 9 d after thyroidectomy (Fig. 7) . As previously reported, the deiodinase in the cerebral cortex reached the levels seen in long-term thyroidectomized rats in -2 d (36) . In addition, this result contrasted with the rapid dissipation of the suppressive effects of T4 on the stimulation of the enzyme induced by cold stress (Fig. 4) . We therefore examined the response of BAT 51)-II to hypophysectomy. Fig. 7 shows that the activity of the enzyme increased rapidly 3-4 d after this procedure, reaching the levels seen in chronically hypothyroid rats in -5 d. Whereas T4 was still present in serum 24 h after hypophysectomy (1.8±0. 2 [SE] gg/dl), the concentrations were not significantly different betwen 48 h and 5 days after the hypophysectomy (0.88±0.4 vs 0.58±0.09 ,g/dl). The time course of the elevation after hypophysectomy, although markedly faster than after thyroidectomy, does not follow the fall in serum T4 as closely as does the BAT 5D-I response to cold-stimulation (Fig. 4) .
These results suggested that there is a pituitary factor that exerts a tonic inhibition on BAT 5D-II. Because the enzyme activity ultimately reaches markedly elevated levels in chronically hypothyroid rats, one may infer that this factor could also be thyroid hormone-dependent. These observations prompted a series of experiments to define the nature of the pituitary-dependent inhibition. Although testosterone was not directly investigated, the removal of the gonadotropins can hardly account for the rapid increment of BAT 5D-I1 after hypophysectomy, in that these animals were sexually immature. Similarly, sexually immature rats and sexually mature rats, regardless ofgender, exhibit equal BAT 5D-I responses to catecholamines and cold stress (Silva, Larsen, manuscript in preparation). Experimental support for endogenous opiates being a pituitary inhibitory factor is also lacking, because the injection of naloxone 40 Mg!100 g BW intravenously 4.5 h before killing followed by two more intraperitoneal injections at -3 and -1.5 h, failed to elevate the BAT 5D-II activity in rats thyroidectomized 24 h previously. In summary, these findings point to GH deficiency which allows BAT 51D-I to rise after hypophysectomy. It is also likely that GH is the factor that explains the delayed increase of BAT 5D-I1 following thyroidectomy. The following experiments were devised to evaluate these hypotheses.
Time course ofBAT 5'D-II elevation, growth rate, and GH reduction after removal ofthyroid hormone. To further our understanding of the delayed response of BAT 5D-II to the removal of thyroid hormone, 75-80-g rats were given 0.02% MMI in the drinking water, and serum T4, T3, GH response to pentobarbital, body weight gain, and BAT 5'D-II were measured after 1, 2, and 3 wk. The results are depicted in Fig. 9 . They show that by 1 wk after starting MMI, the serum concentrations of T4 and T3 were maximally reduced. By this time the pituitary GH, as assessed by its response to pentobarbital, was -20% of the basal and it continued to decrease, reaching 10% of control, after 2 wk on MMI. Body weight was measured over the last 3-4 d of each week and used as an expression ofGH action, because rats of this age are growing rapidly. By 1 wk the mean weight gain per day was reduced by~-30%, (not significantly), it remained unchanged during the second week, and it ceased in the third week. The upper part of Fig. 9 shows that BAT 5D-II remained low during the first 2 wk, but increased dramatically during the third week of MMI treatment.
Effects ofGH and T3 in chronically hypothyroid rats. Because GH levels are reduced in chronically hypothyroid rats, we explored the effect of repeated injections ofbGH on 5D-II activities in various tissues in these rats. The results (Table II) showed that 5 d of bGH administration to hypothyroid rats reduced the levels of BAT 5D-Il by 40% but did not affect the levels of this enzyme in the cerebral cortex or pituitary gland. We also explored further the partial prevention by T3 of the increase in BAT 5D-Il activity after hypophysectomy (Fig. 7) , inasmuch as this contrasts with absence of an acute effect of T3 on hypothyroid rats or cold-stimulated BAT 5'D-II (Fig. 2, Fig.  5 ). One explanation for the results was that T3 potentiated the effect of residual GH, somatomedin C, or other growth factors, the half-life of which was longer than that of GH itself. In this study hypophysectomized rats were maintained on 5% glucose for 5 wk. At this time, one group of animals was given 0.025 mg of bGH/100 g BW twice daily, i.e. only one-fourth of the dose used previously (Fig. 7 and Table II ). Another group received GH plus 0.15 ,eg of T3/ 100 g BW twice daily, and a third received T3 alone in the same dosage. The treatments lasted for 5 d and the results are shown in Table III . T3 alone, in a dose that normalized liver a-GPD, caused a 40% reduction in the BAT 5'-deiodinase. GH alone caused a 60% reduction in the 5'D-I levels and, when given with T3, caused an 84% reduction ofthe enzyme activity. The differences among the various treatment groups were all significant by the Neuman-Keuls test, suggesting that T3 has a modest intrinsic effect which is additive to that of GH. The significant, albeit small, effect of replacement doses ofT3 in this experiment contrasts with the lack ofan acute decrease in the enzyme after large doses of T3 in chronically hypothyroid rats. This suggests that the effect of prolonged T3 replacement on BAT 5D-II is mediated through different mechanisms from those involved in the suppression by T4 or rT3.
Effect of T3 replacement in long-term hypothyroid rats upon growth, hepatic a-GPD and BAT 5'D-II. Rats with long-term hypothyroidism were injected with 0.3 gg of T3/100 g BW per day subcutaneously for either 2 or 7 d. The animals were weighed daily and liver mitochondrial. a-GPD and BAT 5D-II were measured. The results are shown in Table IV . By 7 d oftreatment weight gain increased significantly and a-GPD was normalized. However, BAT 5D-II was reduced only by 70%, remaining severalfold higher than in control rats (for normal values see Tables  II and III) . The rats treated for only 2 d showed no significant increase in weight, an increase in a-GPD to -30% of normal, i.e., of the rats treated for 7 d, and no change in BAT SD4Il.
Relative to controls, the BAT 5D-II reduction induced by 7 d of T3 in hypothyroid rats was significantly greater than that observed in hypophysectomized rats (Table III) , suggesting that in All values are the mean±SEM for each treatment group, the number of rats being indicated in parentheses. Rats were hypophysectomized and received 5% glucose (see Methods) for 5 wk before the treatments were started. Treatments consisted of GH, 0.05 mg/I00 g BW per day
subcutaneously, or T3, 0.3 Mug/I00 g BW per day subcutaneously, or both combined. Doses were divided into two daily injections and were given for 5 d. Rats were killed the day after the last injection. During the period of treatment all hypophysectomized rats received corticosterone 0.5 mg/100 g BW twice daily in subcutaneous injections. Abbreviations: GH, growth hormone; AOV, analysis of variance; BAT 51D-Il, brown adipose tissue type II 5'-deiodinase; a-GPD, alpha glycerophosphate dehydrogenase.
thyroidectomized rats part of the effect of chronic T3 administration could be due to an increase in GH levels in the pituitary and in the serum, as observed in the present experiments (Table IV) . Response ofBAT and cortex S'D-II to T4 withdrawal in hypophysectomized rats treated with T4. To confirm that the failure of BAT 5'1-II to rise abruptly after thyroidectomy was due to pituitary-related mechanisms and not to one extrapituitary message induced by thyroid hormone, hypophysectomized rats were given T4 (0.8 ,ug/100 g BW per day) starting 18 d after surgery.
Treatment was continued for 1 wk and rats were sacrificed at various times after discontinuing T4. The results of this experiment are shown in Fig. 10 . In contrast to the delayed increase in BAT 5D-II after thyroidectomy (Figs. 7 and 10 ), or during MMI treatment (Fig. 9) , 5'D-II activity increased at the same rate in BAT and cerebral cortex, closely reflecting the fall of serum T4.
Discussion
The present studies confirm that the BAT 5D-II is elevated in animals with long-term hypothyroidism and, further, that the enzyme responds to the acute injection of T4 and rT3 in the same manner as it does in the pituitary and the cerebral cortex. In all three tissues the enzyme is highly responsive to T4 and rT3, and much less so to the acute injection of T3 (18) . As in cerebral cortex and the anterior pituitary gland, the acute iodothyronine-mediated suppression ofthe enzyme activity in BAT does not require protein synthesis, and the iodothyronines appear to accelerate the disappearance or inactivation of the enzyme.
Whereas for the cerebrocortical and pituitary 5'D-II, the primary regulatory input identified to date is the serum or tissue T4 concentrations, BAT 5D-Il seems to be under a more complex control. We have reported earlier (22) that BAT 5'D-II is markedly stimulated by NE via an a-I receptor, a property not shared by the cerebrocortical and pituitary SD-1I. The present studies show that the expression of the enzyme activity depends not only on thyroid hormone and the sympathetic nervous system, but is also under the inhibitory influence of GH or GH-dependent processes. This possibility was first raised when we noted there was no immediate increase in BAT 5D-IT after thyroidectomy. Whereas the pituitary and cerebrocortical 5D-II increased within 24-48 h in the same rats, 2-3 wk were required to obtain maximal levels in BAT. This long delay was not observed after hypophysectomy as maximal and similar levels of BAT 5)-IT were observed within 5 d. When hypophysectomized animals were given various replacement hormones, only GH prevented the rise in BAT 5D-II. This effect of GH was evident when the hormone was injected 4 d but not when it was given acutely on the fifth day after hypophysectomy. This finding, long-lived messenger. Lastly, the possibility that there is a marked sympathetic activation after hypophysectomy that does not follow the thyroidectomy also seems unlikely in that the treatment of hypophysectomized rats with a-methyl p-tyrosine for 30 h did not induce a reduction in the enzyme activity (data not shown), whereas this treatment prevents the cold-induced activation of BAT 5'D-II (22) . Although the conclusion that the pituitary gland exerts a tonic inhibitory control on BAT 5'D-II largely through GH, is well supported, it seems evident that there are intermediate steps involved. Serum GH has a very short half-life, but the bioassayable sulfation factor, takes -24 h to disappear after hypophysectomy (39). This factor, or a similar one dependent on GH, may explain the 3-4-d delay in the elevation of the enzyme after hypophysectomy (Fig. 7) . This view is consistent with our findings in rats given MMI. Within a week, the serum levels of T4 and T3 had reached a nadir and the pituitary content of GH had been markedly reduced. However, it was not until the third week of methimazole that the rate of weight gain was significantly reduced, suggesting that GH-dependent growth factors or their effects take much longer to dissipate than does the primary signal. This interpretation is supported by data of Burstein et al. (38) who showed that it took several weeks after the level of T4 became undetectable, to see a marked reduction in the levels of insulinlike growth factor (IGF). In their experiments the weight of the animals correlated closely with the serum IGF concentration. Our data are also consistent with those of Coiro et al. (37) , who reported that the pituitary GH levels become significantly reduced about a week after thyroidectomy. Also interesting in this study was that the reduction in the pituitary GH was not reflected in the serum GH levels until about a week later, suggesting that the secretion rate of GH may be maintained in spite of reduced pituitary GH stores. This may be another factor contributing to a delay in the reduction of the tonic pituitary-dependent suppression of BAT 5D-1II. This may be reflected in the sustained growth rate we observed I and 2 wk after MMI, times at which the pentobarbital-stimulated serum GH had decreased markedly. Coiro et al. (37) also found that the rate of gain in body weight in growing rats decreases significantly only 7-10 d after thyroidectomy which is consistent with our findings, given the slower onset of hypothyroidism after the administration of antithyroid drugs. Altogether, these data suggest that the failure of BAT 5'D-II to increase after thyroidectomy is due to the delayed disappearance of GH and GH-related factors, probably IGF.
The increment in cerebrocortical 5'D-II after thyroidectomy is due to a prolongation of the half-life of the active enzyme (27) (40) , and plasma NE is also increased in this circumstance (41, 42) . The present results only indicate that lack of T4, both because of its "specific" effect on enzyme turnover and as the precursor of the metabolic stimulator T3, and "GH deficiency" are contributing to this phenomenon. An important physiologic implication ofthe delayed response of BAT 5D-II to the removal of thyroid hormone in otherwise intact animals is that this tissue would not contribute significantly to the T3 pool at early stages of hypothyroxinemia. During the days after a decrease in serum T4 levels, as occur after MMI or after starting an iodine-deficient diet, thyroidal T3 secretion, driven by the increased levels of TSH, is the main mechanism maintaining serum T3 levels (Larsen et al. [1] for review). It is in animals with medium-to long-term hypothyroidism where the increased fractional rate of T4 to T3 conversion by 5D-II occurs, which may reflect the participation of the BAT enzyme (21) .
In summary, in spite of the similarities between the type II 5'-deiodinase ofthe BAT and that ofthe cortex and the pituitary gland at an enzyme kinetic level, the physiologic regulation differs markedly. In all tissues the fractional turnover rate ofthe enzyme is accelerated by T4 and other iodothyronines in such a way that the steady-state levels of enzyme activity in euthyroidism are only a minor fraction of the levels seen in hypothyroidism. However, whereas in the pituitary and central nervous system the turnover of the enzyme is maintained solely by T4, this does not seem to be the case in BAT, where there are many other signals regulating the expression of the enzyme, either by maintaining tonic inhibition or by stimulation.
Much evidence has been adduced in recent years that points to BAT as an important organ in nonshivering thermogenesis in animals, in the newborn human, and perhaps in the adult as well. Diet-induced BAT thermogenesis, also mediated by the sympathetic nervous system, may be important in the maintenance of normal weight (43) . The increase in local and systemic T3 production by BAT 5`D-II after cold exposure (23) is physiologically sound in that both the sympathetic stimulation and the extra T3 will contribute to heat production. It is interesting to note that in the genetically obese ob/ob mouse, neither the thermogenic nor the 5'D-II response of BAT to sympathetic stimulation is observed (44) . Although the role of increased BAT 5'D-II in hypothyroidism can be readily viewed as a compensatory mechanism, the physiologic role of the dual tonic suppression by T4 and GH are not as easy to explain. Because the enzyme can be markedly stimulated by the sympathetic nervous system and also by insulin and glucagon the dual negative control may be a device to control its activity more finely allowing at the same time a wider response under extreme circumstances.
Certainly more work will be necessary to unravel these complex interrelationships. Furthermore, the multiplicity of perturbations in other hormone systems after endocrine manipulations raises the possibility of secondary effects, i.e., effects mediated through the action of the hormones in other systems or interactions among the hormones themselves at different levels. To clarify the interpretation of these events, it will be mandatory to have available an in vitro system to differentiate primary from secondary and tertiary effects. Notwithstanding, the present results show that the 5'-iodothyronine deiodinase of the brown adipocyte is a target for many of the hormone regulating metabolic processes in humans. As such, it promises to serve an important function as a model for understanding synergistic and antagonistic actions between these fundamental hormonal systems. Given the marked effects of fluctuations in BAT 5D-II on BAT T3 content and on serum T3 (23) , changes in the activity of this enzyme are physiologically important regardless whether they result from direct or indirect action of various hormones on this tissue.
